Your browser doesn't support javascript.
loading
Cost-effective approach to the diagnostic workup of B cell lymphoproliferative disorders via optimal integration of flow cytometric data.
Mason, E F; Morgan, E A; Pinkus, G S; Pozdnyakova, O.
Afiliação
  • Mason EF; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Morgan EA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Pinkus GS; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
  • Pozdnyakova O; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Int J Lab Hematol ; 39(2): 137-146, 2017 Apr.
Article em En | MEDLINE | ID: mdl-28133951
ABSTRACT

INTRODUCTION:

The workup of lymphoproliferative disorders (LPDs) involves the combined use of flow cytometry (FC) and immunohistochemistry (IHC). This often results in duplicate immunophenotypic testing and adds costs that may not be eligible for reimbursement based on the Medicare National Correct Coding Initiative. We aimed to establish a cost-effective diagnostic algorithm based on initial FC categorization to reduce repetitive immunophenotyping.

METHODS:

We retrospectively reviewed 242 cases of suspected LPDs with concurrent FC and IHC testing over a 12-month period. We correlated FC with surgical diagnoses and evaluated the frequency of repeat IHC testing.

RESULTS:

Repetitive immunophenotyping was common; overall, 85% of cases had at least one marker repeated. Concordant cases were significantly less likely to have markers repeated than discordant cases. Of concordant B cell malignancies, 57% represented recurrent disease; however, repeat marker usage was not decreased as compared to new diagnoses. The most frequently repeated markers were CD3, CD5, CD10, and CD20.

CONCLUSIONS:

We propose that in concordant cases, CD5 and CD10 should not be repeated by IHC; this would decrease the use of these markers by 80% and 76%, respectively. We developed an algorithmic approach to IHC usage that has improved incorporation of FC data at our institution and may reduce healthcare costs.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 Base de dados: MEDLINE Assunto principal: Algoritmos / Análise Custo-Benefício / Transtornos Linfoproliferativos Tipo de estudo: Diagnostic_studies / Health_economic_evaluation / Observational_studies Limite: Humans Idioma: En Revista: Int J Lab Hematol Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 Base de dados: MEDLINE Assunto principal: Algoritmos / Análise Custo-Benefício / Transtornos Linfoproliferativos Tipo de estudo: Diagnostic_studies / Health_economic_evaluation / Observational_studies Limite: Humans Idioma: En Revista: Int J Lab Hematol Ano de publicação: 2017 Tipo de documento: Article